event-trade登录编辑
FierceBiotechCodex · 实盘不做把握 7/10
北京时间·🕒 发布 20:39:00时区推断·⟳ 抓取 21:09:53·⚡ 决策 08-04 21:19:26 +9m33s·83.9 天前

KKR拟以每股127美元现金收购Integer并将其私有化

Integer获127美元/股全现金私有化报价,官方公告确认交易企业价值约57亿美元,方向上对Integer股东为正面。

📄 原文FierceBiotech↗ 原文
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer…
不做 Integer Holdings(ITGR.US)
不做:127美元现金收购条款已提前泄露并由官方确认,ITGR已收至124.50美元,剩余约2%毛价差主要是并购套利而非短线事件edge。
不做 KKR(KKR.US)
不做:57亿美元EV收购对KKR属于组合扩张,未披露能短期改变其收入、利润或资本回报的市值级增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

🔎 新鲜度:最早出现 2026-08-01 · 扩散 high · price-in 风险 high ↗ ↗ ↗

消息传播链

  1. 2026-08-01首发WSJ/FT非一手原文 ↗
    WSJ/FT已提前报道KKR接近以约125-130美元/股收购Integer,核心价格区间已泄露。
    市场反应:报道提到Integer此前已因交易谈判消息大涨。
  2. 2026-08-03官方确认/否认Integer/KKR公司公告一手源原文 ↗
    Integer和KKR正式宣布127美元/股全现金收购协议,交易EV约57亿美元,预计年内完成且无融资条件。
  3. 2026-08-03市场反应FierceBiotech转述非一手原文 ↗
    Fierce报道Integer在消息公布后收涨约2.7%至124.50美元,距127美元现金对价仅约2%价差。
    市场反应:ITGR收盘124.50美元,短线主要反应已完成。
  4. 2026-08-04 09:09 ET财经媒体扩散FierceBiotech非一手原文 ↗
    Fierce在次日早盘前扩散该交易,已不是低扩散首发。

关键理由

  • Integer获127美元/股全现金私有化报价,官方公告确认交易企业价值约57亿美元,方向上对Integer股东为正面。
  • 该交易已由WSJ/FT在正式公告前数日泄露,且Integer在公告日已收至124.50美元,距127美元现金对价仅约2.0%毛价差。
  • 对KKR而言57亿美元EV交易相对其资产管理规模和市值不是短线市值级增量,更多是组合扩张而非可交易催化。

主要风险

  • Integer剩余价差主要是股东批准、监管审批和年内交割的并购套利风险,不适合本系统短线事件仓。
  • 若出现竞购方或更高报价才会形成新催化,本条当前信息已基本被市场消化。

原文全文

展开原文 · 2,366 字
Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
Plano, Texas-based Integer saw its shares climb after news of the sale was announced Monday, closing up about 2.7% at $124.50 per share.
Under the deal, KKR will pay Integer stockholders $127 per share in cash. The approximately $5.7 billion enterprise value includes the assumption of Integer’s outstanding debt. The companies expect the transaction to close by the end of the year, subject to approval from Integer stockholders and regulators.
Integer reported $1.85 billion in total sales for 2025, an increase of 8% from the previous year.
The device CDMO is a key global supplier of components and finished medtech products used in cardiovascular and neuromodulation therapies, among other areas. The company has about 11,000 employees.
The deal represents another move by a private equity firm looking to enter or expand its footprint in healthcare. Recent deals include American Industrial Partners’ approximately $1.27 billion acquisition of Avanos and Blackstone and TPG’s acquisition of diagnostics company Hologic in a transaction valued at up to $18.3 billion.
In March 2025, Sycamore Partners agreed to acquire drugstore giant Walgreens in a deal with an equity value of nearly $10 billion.
“Integer is an exceptional platform with highly differentiated capabilities across a global manufacturing footprint, a track record for quality and reliability, and a talented team operating in attractive, durable end-markets,” Max Lin, a KKR partner, said in a statement.
Upon completion of the acquisition, KKR said it intends to establish a “broad-based employee ownership and engagement program” consistent with the investment firm’s strategy of cultivating an ownership culture at companies in its portfolio.
“We believe this transaction recognizes the strength of Integer’s business, which includes our dedicated associates, our differentiated engineering and manufacturing capabilities, and our long-term growth opportunities, while providing stockholders with immediate and certain value,” Integer President and CEO Payman Khales said.
Goldman Sachs served as Integer’s exclusive financial adviser, while Centerview Partners, Barclays, Citi and Raymond James served as financial advisers to KKR.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。